Targeted Protein Degradation: How PROTACs and Molecular Glues Are Revolutionizing Drug Discovery
Targeted protein degradation has reshaped drug discovery by moving beyond traditional occupancy-driven inhibition to harness the cell’s own quality-control systems. Approaches such as PROTACs (proteolysis-targeting chimeras) and molecular glues recruit E3 ubiquitin ligases to mark disease-causing proteins for degradation, offering routes to tackle so-called “undruggable” targets and to achieve sustained pharmacology at lower systemic exposure.Why it matters
– Broader target space: Degraders can eliminate scaffolding or non-enzymatic proteins that are difficult to inhibit with classical small molecules.
– Improved potency and duration: Catalytic mechanisms allow a single degrader molecule to trigger destruction of multiple target proteins, often giving prolonged effects after compound clearance.
– Potential to overcome resistance: For targets that mutate to evade inhibitors, removing the protein altogether presents an alternative therapeutic strategy.
Key scientific advances
– Expanded E3 ligase toolkit: Research has identified and validated ligases beyond the commonly used CRBN and VHL, enabling tissue-selective degradation and reducing on-target toxicity risks.
– Design strategies: Structure-based design, covalent chemistries, and fragment-based approaches are refining the linker and ligand combinations that control ternary complex formation and degradation kinetics.
– Selectivity tuning: Optimizing ternary interface energetics and exploiting differences in target surface topology improves degradation selectivity over closely related proteins.
– Oral bioavailability and PK: Chemical modifications and smart linker design have improved cell permeability and metabolic stability, making oral degrader candidates more viable.
Practical challenges to address
– Predicting ternary complex formation: Reliable in silico and in vitro models are still evolving for forecasting which ligand-linker combinations will produce stable, productive ternary complexes.
– Off-target degradation: Unintended recruitment of non-target proteins can cause toxicity; comprehensive proteomics and functional screening are essential during lead optimization.
– Pharmacokinetics/pharmacodynamics (PK/PD) disconnects: Potency in cellular assays doesn’t always translate to in vivo efficacy. Balancing potency with favorable ADME properties remains a central optimization task.
– Resistance mechanisms: Cellular adaptation through E3 ligase mutation, upregulation of compensatory pathways, or altered ubiquitin-proteasome activity requires combination strategies and next-generation degrader designs.
Emerging directions
– Molecular glues as minimalist degraders: Small molecules that stabilize a neo-interface between an E3 ligase and target are often smaller and more drug-like than bifunctional PROTACs, opening new routes toward oral agents.
– Tissue- and cell-type selectivity: Leveraging ligase expression profiles and prodrug strategies can confine degradation activity to desired tissues, improving safety margins.
– Covalent and irreversible degraders: These aim to lock in ternary interactions or to target otherwise intractable protein surfaces, but demand careful assessment of off-target reactivity.
– Integrating phenotypic screening and proteomics: High-content and proteome-wide readouts accelerate identification of functional degraders and uncover unintended liabilities early.
What to look for next
Innovations that improve predictive design—combining structural biology, biophysics, and machine-guided chemistry—will accelerate discovery cycles. Success will hinge on robust translational models that link cellular degradation profiles to therapeutic outcomes. As strategies mature for selectivity, delivery, and resistance mitigation, targeted protein degradation will increasingly complement or replace traditional modes of inhibition across oncology, neurological disorders, and immune-mediated diseases.
For teams pursuing degrader programs, prioritizing mechanistic understanding, comprehensive off-target profiling, and ADME optimization will be essential to turn promising molecules into safe, effective medicines.